Madrid

• Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease Ended recruitment
  2023-504471-25-00 5 2024-03-01 Fibrotic Lung Disease
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal- … Ended recruitment
  2022-502446-27-00 5 2024-02-26 Relapsed or Refractory Myeloma
• Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma Ended recruitment
  2023-505205-16-00 4 2024-02-21 Treatment Naïve Mantle Cell Lymphoma
• A first-in-human study to learn about how safe BAY 3375968 is, how it moves into, through, and out of the body, and to find its best dose wh … Ended recruitment
  2023-505594-32-00 1 2024-02-20 Advanced solid tumors
• A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended recruitment
  2023-503827-25-01 5 2024-02-16 Non-Small Cell Lung Cancer (NSCLC)
• A phase Ib dose finding study assessing safety and activity of [177Lu]Lu-NeoB in combination with ribociclib and fulvestrant in participants … Ended recruitment
  2022-502465-18-00 9 2024-02-15 Advanced or metastatic breast cancer
• A study to evaluate the efficacy, safety, and tolerability of using an oral once-daily 2 drug regimen compared to an oral once-daily 3 drug … Ended recruitment
  2023-504993-40-00 5 2024-02-14 Human immunodeficiency virus (HIV)
• A phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered as monotherapy and in combination with cetrelimab and radiotherapy … Ended recruitment
  2023-506393-12-00 1 2024-02-13 Advanced non-small cell lung cancer
• An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended recruitment
  2022-503040-41-00 4 2024-02-09 PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)
• Study of HRO761 alone or in combination in cancer patients with specific DNA alterations called Microsatellite Instability-High or Mismatch … Ended recruitment
  2022-502314-93-00 1 2024-02-05 MSIhi or dMMR advanced unresectable or metastatic solid tumors
• Study to evaluate the efficacy and safety of BGB-11417 in participants with Waldenström’s Macroglobulinemia Ended recruitment
  2023-503235-18-00 4 2024-01-31 previously untreated WM
• A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended recruitment
  2023-503288-40-00 5 2024-01-26 Unresectable or Metastatic Melanoma
• A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma … Ended recruitment
  2023-503575-21-00 5 2024-01-23 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
• Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended recruitment
  2023-503428-24-00 4 2024-01-19 Neoplasms, Head and Neck
• ViaskinTM Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy (VITESSE) Ended recruitment
  2022-502110-85-00 5 2024-01-18 Peanut allergy
• A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S … Ended recruitment
  2022-501622-37-00 5 2024-01-16 Multiple Sclerosis
• DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendo … Ended recruitment
  2023-505870-13-00 3 2024-01-11 Extra-pulmonary neuroendocrine carcinoma (epNEC)
• DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small … Ended recruitment
  2023-506008-20-00 3 2024-01-11 Extensive-stage small cell lung carcinoma (ES-SCLC)
• A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended recruitment
  2022-502442-27-00 5 2024-01-08 Obesity
• A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB … Ended recruitment
  2023-506139-13-00 5 2024-01-04 Treatment naïve patients with MF
• TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of ARV-471 in Combination With Other Medicines in Adults With … Ended recruitment
  2022-502231-19-00 9 2024-01-02 ER+/HER2- Advanced or Metastatic Breast Cancer
• A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or … Ended recruitment
  2023-503452-27-00 5 2024-01-02 Adult patients with follicular B-cell non-Hodgkin lymphoma grade 1-3A,
• TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of Vepdegestrant (ARV-471) in Combination With Other Medicines … Ended recruitment
  2022-502228-34-00 9 2023-12-27 ER +/HER2- Advanced or Metastatic Breast Cancer
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thy … Ended recruitment
  2023-503669-50-00 5 2023-12-27 Moderate-to-Severe Thyroid Eye Disease

Showing 1,945–1,968 of 3,550 trials